文献速递冠心病外科瓣膜外科主动脉外科

del Nido液与含血心脏停搏液在心脏手术中的比较:逾4万例患者的多中心分析

del Nido versus blood cardioplegia in cardiac surgery: A multicenter analysis of over 40,000 patients.
PubMed 文献 · J Thorac Cardiovasc Surg · 2023-10-02

该多中心研究从灌注措施与结局登记库提取2014年7月至2022年3月39个中心接受冠状动脉旁路移植术(CABG)和/或瓣膜(二尖瓣、主动脉瓣)和/或非降主动脉胸主动脉手术的患者,按心脏停搏液类型分层并行多变量混合效应模型风险校正。44,175例中42.5%使用del Nido液,其使用率随时间增加48%;del Nido组中位主动脉阻断时间更短、术中血糖峰值更低,且与手术死亡率及主要并发症无显著相关。

要点

  • del Nido组中位主动脉阻断时间为74分钟,含血心脏停搏液组为87分钟(P < .001)。
  • del Nido组中位术中血糖峰值为161 mg/dL,含血心脏停搏液组为180 mg/dL(P < .001)。
  • del Nido与手术死亡率(ORadj 1.16,P = .075)及主要并发症(ORadj 1.05,P = .25)无显著相关。

核心结论

  • 在这一大型多中心研究中,使用del Nido液与程度不一的主动脉阻断时间差异、更低的术中血糖水平相关,主要并发症或死亡率无显著差异。
  • 作者指出,del Nido液在瓣膜病例中的效率优势可能有限,而CABG和主动脉病例的结局需进一步研究。

研究设计与样本

  • 多中心研究,数据来自灌注措施与结局登记库,纳入2014年7月至2022年3月39个中心接受CABG和/或瓣膜(二尖瓣、主动脉瓣)和/或非降主动脉胸主动脉手术的患者。
  • 按心脏停搏液类型分层进行未校正分析,并采用多变量混合效应模型进行风险校正。

主要发现

  • 44,175例患者中42.5%使用del Nido液,其使用率随时间增加48%。
  • del Nido组中位主动脉阻断时间为74分钟,含血心脏停搏液组为87分钟(P < .001)。
  • del Nido组中位术中血糖峰值为161 mg/dL,含血心脏停搏液组为180 mg/dL(P < .001)。
  • del Nido的使用与手术死亡率(ORadj 1.16,P = .075)及主要并发症(ORadj 1.05,P = .25)无显著相关。
  • 瓣膜病例结果相似,但主动脉阻断时间差异随瓣膜手术类型而异;CABG亚组中del Nido有手术死亡率升高趋势(ORadj 1.24,P = .069),主动脉亚组中肾衰竭风险接近统计学显著(ORadj 1.54,P = .056)。

局限性

  • 原文结论指出,del Nido液在瓣膜病例中的效率优势可能有限,而CABG和主动脉病例的结局需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The use of del Nido cardioplegia in adult cardiac surgery is rising in popularity. The objective of this large multicenter study was to evaluate the use and associated outcomes of del Nido versus blood cardioplegia in adult cardiac surgery. METHODS: Patients undergoing coronary artery bypass grafting (CABG) and/or valve (mitral, aortic), and/or nondescending thoracic aortic surgery (July 2014 to March 2022) across 39 centers were extracted from the Perfusion Measures and Outcomes registry. Patients were stratified by cardioplegia type for unadjusted analysis and multivariable mixed-effects models were used for risk adjustment. RESULTS: Of 44,175 patients, 42.5% used del Nido, with use increasing 48% over time. Overall, the del Nido group had shorter median crossclamp time (74 minutes vs 87 minutes, P < .001) and lower median peak intraoperative glucose levels (161 mg/dL vs 180 mg/dL, P < .001). Use of del Nido was not associated with operative mortality (adjusted odds ratio [ORadj], 1.16; P = .075) nor major morbidity (ORadj, 1.05; P = .25). Findings for valve cases were similar, except crossclamp time differences were variable by type of valve procedure. Within the CABG subgroup there was a trend toward increased operative mortality with del Nido (ORadj, 1.24; P = .069), whereas the risk of renal failure approaches statistical significance in the aortic subgroup (ORadj, 1.54; P = .056). CONCLUSIONS: In this large, multicenter study, the use of del Nido was associated with variable crossclamp time differences, lower intraoperative glucose levels, and no significant difference in major morbidity or mortality. Efficiency benefits of del Nido may be limited in valve cases, whereas outcomes in CABG and aortic cases warrant further study.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Hawkins RB, Stewart JW, Wu X, et al. del Nido versus blood cardioplegia in cardiac surgery: A multicenter analysis of over 40,000 patients. J Thorac Cardiovasc Surg. 2023. PMID: 37793563. doi:10.1016/j.jtcvs.2023.09.057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。